Comparative Pharmacology
Head-to-head clinical analysis: EYDENZELT versus KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EYDENZELT versus KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE.
EYDENZELT vs KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EYDENZELT (bexarotene) is a retinoid that selectively binds to and activates retinoid X receptors (RXRs), which regulate gene expression involved in cell differentiation, proliferation, and apoptosis. It induces apoptosis and inhibits cell growth in malignant T-cells.
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Phenylephrine is a selective alpha-1 adrenergic receptor agonist, causing vasoconstriction.
1 mg subcutaneously once weekly.
Ophthalmic: 1 drop of the combination (ketorolac tromethamine 0.45% and phenylephrine hydrochloride 1%) into the operative eye three times daily, beginning 1 day prior to surgery and continuing on the day of surgery and for 2 weeks postoperatively.
None Documented
None Documented
Terminal elimination half-life is approximately 12-14 hours, allowing once-daily dosing with steady-state reached within 3-5 days.
Ketorolac: 2.4-8.6 hours (mean 5.3 hours) in young adults; prolonged in elderly (up to 13.9 hours) and renal impairment. Phenylephrine: 2-3 hours.
Primarily renal excretion as unchanged drug (approximately 70-80%) and minor fecal elimination (≤10%). Biliary excretion is negligible.
Ketorolac: ~92% renal (60% as unchanged drug, 32% as metabolites), 6% fecal. Phenylephrine: primarily renal as metabolites (sulfate conjugates) with <1% unchanged.
Category C
Category D/X
NSAID
NSAID